--- title: "Cue Biopharma (CUE) news: reverse split and going concern" url: "https://aibio.space/companies/cue-biopharma/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "CUE reverse split, going concern and offering news: Cue Biopharma sets 1-for-30 reverse stock split for April 23, 2026. Cue Biopharma, Inc." --- CUE Cue Biopharma, Inc. NASDAQ · United States # Cue Biopharma (CUE) news CUE reverse split, going concern and offering news Financings · 2026-07-10 ## [Cue Biopharma agrees to $50.0 million private placement led by Cormorant](https://aibio.space/news/cue-biopharma-agrees-50-0-million-private-placement-led-cormorant/) Cue will sell 1,418,071 shares at $33.21 and pre-funded warrants for up to 87,500 shares, for gross proceeds of about $50.0 million. Cormorant Asset Management led. The 8-K also reports RSU grants to officers and directors. ## Latest Cue Biopharma news 1. 2026-07-10 Financings [Cue Biopharma agrees to $50.0 million private placement at $33.21 a share](https://aibio.space/news/cue-biopharma-agrees-50-0-million-private-placement-33-21-share/) Cue Biopharma is selling 1,418,071 shares at $33.21 and pre-funded warrants for up to 87,500 shares, for about $50.0 million in gross proceeds. Its release says the lead candidate is advancing toward Phase 1, while its annual report calls that candidate preclinical. 2. 2026-05-01 Financings [Cue Biopharma licenses Ascendant-221 from Ascendant Health, to pay $15.0 million upfront](https://aibio.space/news/cue-biopharma-licenses-ascendant-221-ascendant-health-pay-15-0-million/) Cue Biopharma agreed to pay a $15.0 million upfront for rights to Ascendant-221, an anti-IgE antibody still in a Phase 2 study run by the licensor's affiliate, and to issue pre-funded warrants for up to 551,724 shares. Milestones could reach $676.5 million, and the company's own release cites a current going concern determination. 3. 2026-04-22 Listings [Cue Biopharma sets 1-for-30 reverse stock split for April 23, 2026](https://aibio.space/news/cue-biopharma-sets-1-30-reverse-stock-split-april-23-2026/) Cue Biopharma's 1-for-30 reverse split takes effect at 5:00 p.m. Eastern Time on April 23, 2026. The company says it is meant to restore compliance with Nasdaq's minimum bid price, and its filing still carries a going-concern determination. 4. 2026-04-13 Listings [Cue Biopharma holders approve reverse split range of 1-for-30 to 1-for-50](https://aibio.space/news/cue-biopharma-holders-approve-reverse-split-range-1-30-1-50/) Cue Biopharma holders approved a reverse split at a ratio between 1-for-30 and 1-for-50. The board will pick the ratio and the timing without another stockholder vote, and the filing does not say why the split is wanted. ## Cue Biopharma at a glance - **Ticker**: CUE - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $17.4 million ### Related companies - [Altimmune](https://aibio.space/companies/altimmune/) NASDAQ: ALT - [CorMedix](https://aibio.space/companies/cormedix/) NASDAQ: CRMD - [Bright Minds Biosciences](https://aibio.space/companies/bright-minds-biosciences/) CSE: DRUG - [MetaVia](https://aibio.space/companies/metavia/) NASDAQ: MTVA - [Neurocrine Biosciences](https://aibio.space/companies/neurocrine-biosciences/) NASDAQ: NBIX - [Conexeu Sciences](https://aibio.space/companies/conexeu-sciences/) NASDAQ: CNXU - [BioAtla](https://aibio.space/companies/bioatla/) OTC: BCAB - [Precigen](https://aibio.space/companies/precigen/) NASDAQ: PGEN ### Also on NASDAQ - [Kymera Therapeutics](https://aibio.space/companies/kymera-therapeutics/) KYMR - [Cosmos Health](https://aibio.space/companies/cosmos-health/) COSM - [YD Bio](https://aibio.space/companies/yd-bio/) YDES - [Kalaris Therapeutics](https://aibio.space/companies/kalaris-therapeutics/) KLRS - [CNS Pharmaceuticals](https://aibio.space/companies/cns-pharmaceuticals/) CNSP - [Ceribell](https://aibio.space/companies/ceribell/) CBLL ## What Cue Biopharma does Cue Biopharma is a clinical-stage biopharmaceutical company developing injectable therapeutics that selectively engage and modulate disease-specific T cells for autoimmune and inflammatory diseases. Its Immuno-STAT platform is designed to modulate disease-relevant T cells, and the company describes it as flexible and modular. Its lead candidate, CUE-401, is a preclinical bifunctional fusion protein that combines engineered variants of TGF-beta and IL-2 to induce regulatory T cells and reduce pro-inflammatory autoreactive cells. The company is preparing to file an investigational new drug application in the second quarter of 2026 and anticipates receiving human safety data starting in the second half of 2026. The CUE-500 series redirects anti-viral memory T cells to deplete pathogenic cells, and CUE-501 is licensed to Boehringer Ingelheim International GmbH for autoimmune B cell depletion. In oncology, CUE-101 and CUE-102 have been licensed to ImmunoScape Pte. Ltd., which is developing a Seed-and-Boost immunotherapy that combines them with its tumor-specific T cell receptors. | Product or program | What it is | Stage | |---|---|---| | CUE-401 | Bifunctional TGF-beta and IL-2 fusion protein for autoimmune diseases | preclinical; IND filing being prepared for the second quarter of 2026 | | CUE-501 | Redirects anti-viral T cells to deplete autoreactive B cells | | | CUE-101 and CUE-102 | T cell activators for HPV+ cancers and WT1-expressing cancers | licensed to ImmunoScape Pte. Ltd. for oncology | Summarised from the company's [10-K filed Mar 16, 2026](https://www.sec.gov/Archives/edgar/data/1645460/000119312526108287/cue-20251231.htm). ## Cue Biopharma annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$27.5 million](https://www.sec.gov/Archives/edgar/data/1645460/000119312526108287/) | [$9.3 million](https://www.sec.gov/Archives/edgar/data/1645460/000119312526108287/) | | Research and development | [$37.7 million](https://www.sec.gov/Archives/edgar/data/1645460/000119312526108287/) | [$36.3 million](https://www.sec.gov/Archives/edgar/data/1645460/000119312526108287/) | | Net income (loss) | [-$26.6 million](https://www.sec.gov/Archives/edgar/data/1645460/000119312526108287/) | [-$40.7 million](https://www.sec.gov/Archives/edgar/data/1645460/000119312526108287/) | | Cash from operations | [-$21.7 million](https://www.sec.gov/Archives/edgar/data/1645460/000119312526108287/) | [-$36.3 million](https://www.sec.gov/Archives/edgar/data/1645460/000119312526108287/) | | Cash and equivalents | [$27.1 million](https://www.sec.gov/Archives/edgar/data/1645460/000119312526352128/) | [$22.5 million](https://www.sec.gov/Archives/edgar/data/1645460/000119312526108287/) | | Short-term investments | | [$0](https://www.sec.gov/Archives/edgar/data/1645460/000119312525277466/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $17.4 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Cue Biopharma Did Cue Biopharma do a reverse stock split? Our latest story on this, dated Apr 22, 2026: "Cue Biopharma sets 1-for-30 reverse stock split for April 23, 2026". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/cue-biopharma-sets-1-30-reverse-stock-split-april-23-2026/). Has Cue Biopharma issued a going-concern warning? Our latest story on this, dated May 1, 2026: "Cue Biopharma licenses Ascendant-221 from Ascendant Health, to pay $15.0 million upfront". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/cue-biopharma-licenses-ascendant-221-ascendant-health-pay-15-0-million/). Has Cue Biopharma raised money recently? Our latest story on this, dated Jul 10, 2026: "Cue Biopharma agrees to $50.0 million private placement led by Cormorant". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/cue-biopharma-agrees-50-0-million-private-placement-led-cormorant/). What is the ticker symbol of Cue Biopharma? Cue Biopharma, Inc. trades under the ticker CUE on NASDAQ. Where is Cue Biopharma listed? Cue Biopharma, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:1UC0; LSX:A426PN. What is the SEC CIK of Cue Biopharma? The SEC Central Index Key (CIK) for Cue Biopharma, Inc. is 1645460. Its filings are on SEC EDGAR. How many shares does Cue Biopharma have outstanding? 7,264,414 shares as of 2026-08-12, per the cover page of its 10-Q filed 2026-08-14. Which country or territory is Cue Biopharma listed under? Our directory records Cue Biopharma, Inc. under United States. What does Cue Biopharma do? Our directory classifies Cue Biopharma, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Cue Biopharma? The ISIN recorded for Cue Biopharma, Inc. is US22978P2056. Does aibio.space cover Cue Biopharma? aibio.space lists Cue Biopharma, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Cue Biopharma incorporated? SEC records list its state or country of incorporation as DE. What does Cue Biopharma develop? Cue Biopharma is a clinical-stage biopharmaceutical company developing injectable therapeutics that selectively engage and modulate disease-specific T cells for autoimmune and inflammatory diseases. Its Immuno-STAT platform is designed to modulate disease-relevant T cells, and the company describes it as flexible and modular. What is CUE-401 from Cue Biopharma? CUE-401: Bifunctional TGF-beta and IL-2 fusion protein for autoimmune diseases Stage: preclinical; IND filing being prepared for the second quarter of 2026. What is CUE-501 from Cue Biopharma? CUE-501: Redirects anti-viral T cells to deplete autoreactive B cells Stage: licensed to Boehringer Ingelheim International GmbH; stage not stated. ## Investor discussion: Cue Biopharma Members talk about Cue Biopharma (CUE). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Cue Biopharma, newest first. Each line links the filing it comes from. 1. 2026-07-10 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1645460/000119312526301052/d123955dex991.htm) 2. 2026-05-01 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1645460/000119312526198588/d128047dex991.htm) 3. 2026-04-22 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03). [Source](https://www.sec.gov/Archives/edgar/data/1645460/000119312526168907/cue-20260422.htm) 4. 2026-04-13 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1645460/000119312526152826/cue-20260413.htm) 5. 2026-03-16 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1645460/000119312526108301/cue-20260316.htm) 6. 2026-03-06 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1645460/000119312526096441/cue-20260306.htm) 7. 2025-06-10 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.03,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1645460/000095017025084279/cue-ex99_1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:CUE on TradingView](https://www.tradingview.com/symbols/NASDAQ-CUE/). ## SEC filings and registration - **SEC name**: Cue Biopharma, Inc. - **CIK**: 1645460 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: CUE (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 100 CHESTNUT STREET, SOMERVILLE, MA, 02143 - **Phone**: 617-949-2680 - **Shares outstanding**: 7,264,414 as of 2026-08-12 (10-Q filed 2026-08-14) - **Former names**: Imagen Biopharma, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1645460/000119312526396094/d21238d8k.htm) filed 2026-09-21 - [10-Q](https://www.sec.gov/Archives/edgar/data/1645460/000119312526352128/cue-20260630.htm) filed 2026-08-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1645460/000119312526352126/cue-20260814.htm) filed 2026-08-14 - [S-3](https://www.sec.gov/Archives/edgar/data/1645460/000119312526346867/d136967ds3.htm) filed 2026-08-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1645460/000119312526330730/d134183d8k.htm) filed 2026-08-03 - [8-K](https://www.sec.gov/Archives/edgar/data/1645460/000119312526301052/d123955d8k.htm) filed 2026-07-10 - [S-3](https://www.sec.gov/Archives/edgar/data/1645460/000119312526275808/d44856ds3.htm) filed 2026-06-18 - [8-K](https://www.sec.gov/Archives/edgar/data/1645460/000119312526255479/cue-20260601.htm) filed 2026-06-03 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001645460), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Cue Biopharma, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker CUE, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Cue Biopharma, Inc. - **Ticker**: CUE - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US22978P2056 - **Other listed symbols**: GETTEX:1UC0; LSX:A426PN - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-CUE/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/cue-biopharma/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Cue Biopharma (CUE) news: reverse split and going concern", 2026-10-31, https://aibio.space/companies/cue-biopharma/